Retaane FDA Approval Status

FDA Approved: No
Brand name: Retaane
Generic name: anecortave acetate
Dosage form: Depot Suspension
Company: Alcon
Treatment for: Macular Degeneration

Retaane (anecortave) is an angiostatic cortisene that inhibits the abnormal growth of blood vessels. Retaane suspension is an investigational treatment for preserving the vision of patients with wet age-related macular degeneration (AMD).

Development timeline for Retaane

Date	Article
Sep 25, 2007	Alcon Receives FDA Decision on Retaane Suspension for Wet AMD
May 24, 2005	Alcon Receives Approvable Letter from FDA for Retaane Suspension
Dec 16, 2004	Alcon Submits Retaane - Drug Applications to U.S. and European Regulatory Authorities
Jun 30, 2004	Alcon Updates Filing Status of Retaane New Drug Application

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer